Keyphrases
Clinical Trials
66%
Drug Development
38%
Patient Outcomes
37%
Cuban
33%
Trametinib
33%
Dabrafenib
33%
Cost-plus
33%
Reporting Guidelines
33%
Risk Outcomes
33%
Risk-benefit
33%
Patient Benefit
33%
Ovarian Cancer
33%
Pediatric
33%
Medical Journals
33%
Drug Companies
33%
Medicare
33%
Medicaid
33%
Core Outcome Set
33%
Patient Risk
33%
Clinical Trial Registry
23%
Accelerated Approval
22%
Health Research
19%
Potential Savings
16%
Cancer Clinical Trials
13%
BRAFV600
11%
Malignancy
11%
Health Care Costs
11%
Data Screening
9%
Improved Outcomes
9%
Data Extraction
9%
Multiphysics Object-oriented Simulation Environment (MOOSE)
9%
Instructions to Authors
9%
Overall Survival Progression-free Survival
8%
Patient-reported Outcomes
8%
Standardized Outcomes
8%
Shipping Cost
5%
Antineoplastic Agents
5%
Online Pharmacies
5%
Dabrafenib Plus Trametinib
5%
Pricing Model
5%
Yield Quality
5%
Medicaid Spending
5%
Clinical Drug Trials
5%
Response Evaluation Criteria in Solid Tumors (RECIST)
5%
Company Website
5%
Kinase Inhibitor
5%
Spending Data
5%
Preventative Medicine
5%
Unit Price
5%
Potential Cost Savings
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
66%
Trametinib
33%
Dabrafenib
33%
Ovary Cancer
33%
Fluticasone Propionate
33%
Drug Analysis
33%
Cross Sectional Study
33%
Atopic Dermatitis
33%
Prescription Drug
33%
Overall Survival
11%
Progression Free Survival
11%
Symptom
11%
Clinical Research
8%
Female Genital Tract Cancer
5%
Medicine and Dentistry
Ovarian Cancer
33%
Health Care Cost
33%
Clinical Trial
33%
Medicare
33%
Patient-Reported Outcome
11%
Overall Survival
11%
Progression Free Survival
11%
Symptom
11%
Awareness
11%
Decision Making
5%
Female Genital Tract Cancer
5%
Quality of Life
5%
